Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid
- PMID: 18571472
- DOI: 10.1016/j.clim.2008.04.012
Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid
Abstract
Bullous pemphigoid (BP) is an autoimmune bullous disease, associated with autoantibodies directed against the hemidesmosomal components BP180 and BP230. In this study for the first time different laboratories have analyzed the autoantibody profile in the same group of 49 prospectively recruited BP patients. The results show that: 1) disease severity and activity correlated with levels of IgG against the BP180-NC16A domain, but also against a COOH-terminal epitope of BP180, 2) distinct epitopes of the BP180 ectodomain other than BP180-NC16A were recognized by 96% of the BP sera; and 3) the combined use of BP180 and BP230 ELISA led to the detection of IgG autoantibodies in all the BP sera. These results demonstrate the usefulness of the combined ELISAs based on various BP180 and BP230 fragments in establishing the diagnosis of BP and support the concept that BP180 is the major autoantigen of BP.
Similar articles
-
Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients.Br J Dermatol. 2004 Nov;151(5):1004-10. doi: 10.1111/j.1365-2133.2004.06245.x. Br J Dermatol. 2004. PMID: 15541078
-
Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.J Autoimmun. 2000 Nov;15(3):293-300. doi: 10.1006/jaut.2000.0437. J Autoimmun. 2000. PMID: 11040070
-
IgE autoantibodies against the intracellular domain of BP180.Br J Dermatol. 2009 Feb;160(2):429-32. doi: 10.1111/j.1365-2133.2008.08858.x. Epub 2008 Sep 19. Br J Dermatol. 2009. PMID: 18808416
-
Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.Arch Dermatol. 2000 Apr;136(4):527-32. doi: 10.1001/archderm.136.4.527. Arch Dermatol. 2000. PMID: 10768652 Review.
-
Bullous Pemphigoid Severity and Levels of Antibodies to BP180 and BP230: A Systematic Review and Meta-Analysis.JAMA Dermatol. 2024 Nov 1;160(11):1192-1200. doi: 10.1001/jamadermatol.2024.3425. JAMA Dermatol. 2024. PMID: 39356527
Cited by
-
[Paraneoplastic autoimmune dermatoses].Hautarzt. 2021 Apr;72(4):277-287. doi: 10.1007/s00105-021-04773-w. Epub 2021 Mar 1. Hautarzt. 2021. PMID: 33646324 Review. German.
-
Bullous Pemphigoid: Trigger and Predisposing Factors.Biomolecules. 2020 Oct 10;10(10):1432. doi: 10.3390/biom10101432. Biomolecules. 2020. PMID: 33050407 Free PMC article. Review.
-
Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid.Ann Dermatol. 2012 Feb;24(1):45-55. doi: 10.5021/ad.2012.24.1.45. Epub 2012 Feb 2. Ann Dermatol. 2012. PMID: 22363155 Free PMC article.
-
Serological Diagnosis of Autoimmune Bullous Skin Diseases.Front Immunol. 2019 Aug 20;10:1974. doi: 10.3389/fimmu.2019.01974. eCollection 2019. Front Immunol. 2019. PMID: 31552014 Free PMC article. Review.
-
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.Front Immunol. 2021 Oct 14;12:738907. doi: 10.3389/fimmu.2021.738907. eCollection 2021. Front Immunol. 2021. PMID: 34721404 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical